NYT: In a setback for the fledgling field of personalized medicine, Medicare has decided not to pay for genetic tests intended to help doctors determine the best dose of the blood thinner warfarin for a particular patient.
As the article notes, this view seems to be a odds with the position of the Food and Drug Administration which recommends such genetic test for purposes of dosage selection.
I wonder if economic considerations may not be in play here.
No comments:
Post a Comment